Everand Logo

Welcome to Everand!

  • STAT

    STAT+: Intellia plays down concerns about accidental germline transmission in CRISPR trial

    Over the weekend, Intellia sought to address concerns in the gene editing community about accidental germline transmission.
    by Megan Molteni Aug 21, 2023 1 minute
    Source: Adobe

    Earlier this month, Intellia Therapeutics it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Pfizer’s DTC Platform, Sandoz’s Feud With A U.K. Trade Group, And More
    Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.
    STAT1 min read
    STAT+: No, Alcohol Isn’t Good For You. Will New Dietary Guidelines Be Shaped More By Health Or Industry Interests?
    More and more studies show that alcohol isn't healthy after all. Dietary guidelines are up for revision in 2025, and already, there's debate over research and industry influence.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
    Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.

    Related Books & Audiobooks